You are viewing the site in preview mode

Skip to content

Advertisement

  • Poster presentation
  • Open Access

The impact of cellular senescence and DNA damage on colorectal tumour progression

  • 1, 2, 3,
  • 1, 2, 3,
  • 1, 2, 3,
  • 1, 2, 3,
  • 1, 2, 3,
  • 1, 2, 3,
  • 1, 3, 4,
  • 1, 3, 5,
  • 6 and
  • 1, 2, 3
Journal for ImmunoTherapy of Cancer20131 (Suppl 1) :P144

https://doi.org/10.1186/2051-1426-1-S1-P144

  • Published:

Keywords

  • Immune Cell
  • Telomere Length
  • Cellular Senescence
  • Immune Marker
  • Infiltrate Immune Cell

We have previously defined the immune contexture as the type, density, location and functional orientation of tumour infiltrating immune cells, associated with patient prognosis in colorectal cancer (CRC). Here we describe potential mechanisms, including the DNA damage response (DDR) and cellular senescence, as contributing factors in shaping this intra-tumoural immune reaction. Cellular senescence, permanent proliferation arrest, is triggered by exogenous or endogenous stress, including telomere shortening, DNA-damage or oncogene activation. We have evaluated the expression of 53BP1, pATM and p16INK4a in a cohort of 205 CRC patients. In addition, telomere length and senescence-associated β-galactosidase have been analysed. A large panel of immune markers, including CD3, CD45RO, CD8 and CD57, were evaluated immunohistochemically. Patients who had increased DDR and senescence correlated with improved prognosis, both disease free and overall survival. Patients with high 53BP1 and pATM had significantly higher numbers of infiltrating immune cells at both the tumour centre and invasive margin. Functional experiments, including a transwell chemotaxis system, have illustrated that immune cells migrate towards soluble factors produced by senescent tumour cells. Our data provide further mechanisms resulting in changes of specific immune cell densities within the tumour, illustrating links between senescence and aspects of the DDR with the control of the anti-tumour immune response, and thus CRC disease progression.

Authors’ Affiliations

(1)
Laboratory of Integrative Cancer Immunology, INSERM U872 Paris, France
(2)
Université Paris Descartes, Paris, France
(3)
Cordeliers Research Centre, Université Pierre et Marie Curie Paris 6, Paris, France
(4)
University of Erlangen-Nuremberg, Erlangen, Germany
(5)
Immunology, Georges Pompidou European Hospital, Paris, France
(6)
MedImmune Ltd, Cambridge, UK

Copyright

© Angell et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement